Hemp and CBD Companies vs Marijuana Companies: Different Laws, Different Risks for Investors

This guide is for investors and hemp business owners who see hemp, CBD and marijuana companies grouped together as “cannabis stocks” and want to understand why they behave so differently. It compares the three groups on federal law, taxes, banking, product rules and market size, using the status of each as of November 19, 2026. It does not recommend any company.
This article is for education only and is not investment, legal, or tax advice. Investing involves risk, including loss of principal.
- Hemp is not a controlled substance when it meets the federal definition. Marijuana is, and most of it is still in Schedule I.
- The federal hemp definition is changing. Under P.L. 119-37 and a later delay law, a total-THC standard and a 0.4 mg per-container cap for final products are scheduled to take effect December 11, 2026.
- Marijuana companies face 280E, bank reporting rules and listing barriers that compliant hemp companies mostly avoid. Hemp-derived CBD companies face FDA limits instead.
- The April 2026 rescheduling order helped medical marijuana operators and did not change hemp’s status.
Table of Contents
Same plant, different legal categories
Hemp and marijuana are both Cannabis sativa. Federal law separates them by chemistry, not by species. The Congressional Research Service explains that the 2018 farm bill defined hemp as cannabis and its derivatives with no more than 0.3% delta-9 THC, and removed hemp from the Controlled Substances Act’s definition of marijuana. Anything above that line is marijuana unless another exception applies.
.jpg/960px-Hemp_Farm_MD_(20200814-AMS-RAY-0007).jpg)
That line is moving. In November 2025, Congress rewrote the hemp definition in P.L. 119-37. According to CRS Legal Sidebar LSB11496 (October 28, 2026), the new definition:
- measures total THC rather than only delta-9 THC;
- excludes hemp-derived products containing cannabinoids the plant cannot naturally produce, or that were synthesized outside the plant;
- excludes final hemp-derived cannabinoid products with more than 0.4 mg of total THC and similar cannabinoids per container; and
- expressly includes industrial hemp grown for fiber, grain, oil and other non-cannabinoid uses.
The changes were originally to take effect November 12, 2026. A September 2026 continuing resolution, P.L. 119-103, delayed most of them to December 11, 2026, but let the exclusion for cannabinoids the plant cannot naturally produce take effect on November 12 as planned. CRS lists pending bills that would delay the changes two more years or repeal them. As of November 19, 2026, none had become law. Our explainers on the new federal hemp definition and its market impact go deeper.
Marijuana’s own federal status also moved in 2026. A Justice Department order effective April 28, 2026 placed marijuana in FDA-approved drugs and marijuana under state medical licenses in Schedule III. All other marijuana, including adult-use, remains Schedule I while a broader DEA proceeding is pending. The order states that it does not affect hemp, because hemp is excluded from the definition of marijuana. See our guide to rescheduling and 280E.
Side-by-side comparison
| Factor | Industrial hemp (fiber, grain, seed) | Hemp-derived CBD and cannabinoid products | State-licensed marijuana |
|---|---|---|---|
| Federal status (Nov. 19, 2026) | Not controlled if within the hemp definition | Not controlled if within the definition; intoxicating and high-THC products lose hemp status as the new definition takes effect | Medical: Schedule III. Adult-use: Schedule I |
| Section 280E | Does not apply | Does not apply to compliant hemp | Applies to adult-use activity; order says medical licensees are no longer subject |
| Bank reporting | Standard due diligence (FinCEN 2020) | Standard due diligence for hemp businesses | FinCEN 2014 marijuana guidance, including special SAR filings |
| Product regulator | USDA licensing and THC testing | USDA for the crop; FDA for food, supplements and drugs | State regulators; DEA registration for medical licensees |
| Biggest policy risk | THC testing and definition changes | Per-container THC cap, FDA position, state bans | Litigation over the April order; the pending broader rule; 280E guidance |
Risks specific to hemp and CBD companies
FDA limits on CBD
FDA’s position is that adding CBD or THC to food sold in interstate commerce is prohibited, and that CBD and THC products are excluded from the dietary supplement definition. FDA notes that Epidiolex is the only approved drug containing CBD. In January 2023 the agency concluded that its existing food and supplement frameworks are not appropriate for CBD and said it would work with Congress. Hemp seed ingredients such as hulled seed, seed protein and seed oil are treated separately. So a company selling CBD gummies or drinks carries regulatory risk that a hemp seed food or fiber processor does not.
The per-container THC cap
Once the new definition takes effect, a final hemp-derived product with more than 0.4 mg of total THC per container falls outside the definition of hemp. Many intoxicating hemp products, and some full-spectrum CBD products, would then be treated as marijuana. Executive Order 14370 itself observed that some full-spectrum CBD products would become controlled again under the new law, and it directed White House staff to work with Congress on a different standard. That direction is not law. For investors, the question is how much of a company’s revenue comes from products that will no longer qualify.
Commodity and oversupply risk
Hemp is an agricultural commodity with volatile prices. A processor or brand dependent on one crop type is exposed to that market. Read inventory notes for write-downs, and check whether a company’s stated growth fits the size of its segment (see below).
Thin disclosure
Many hemp and CBD companies are small, and some do not file with the SEC. The SEC’s investor alert on marijuana investments warns that scarce information about microcap stocks makes them easier to manipulate. The same risk applies to hemp names promoted on the back of hemp legislation news.
Risks specific to marijuana companies
Section 280E
Section 280E denies deductions and credits to businesses trafficking in Schedule I or II substances, which can push a cannabis retailer’s effective tax rate above 100%. One large multi-state operator reported a 2025 effective tax rate of 227.5% and more than $668 million in uncertain tax position liabilities at year-end. Medical operators expect relief starting with the 2026 tax year, based on the April order and a Treasury and IRS announcement of planned guidance. As of November 19, 2026, we did not find that guidance published. Adult-use activity is still covered by 280E. Compliant hemp businesses never were, because hemp is not a controlled substance.
Banking and capital
FinCEN’s 2014 guidance requires banks serving marijuana businesses to file suspicious activity reports, even for state-licensed customers. Its 2020 hemp guidance says banks need not file a SAR solely because a customer grows hemp lawfully, and that it does not replace the 2014 marijuana guidance. In Congress, the SAFE Banking Act of 2026 was introduced in the Senate (S. 4942) on June 24, 2026 and in the House (H.R. 9471) on June 25, 2026. As of November 19, 2026, both were still in committee. For the hemp side, see banking and insurance for hemp businesses.
Listing and trading
Companies that touch adult-use marijuana have generally traded on Canadian exchanges and U.S. over-the-counter markets. After the April order, at least one operator restructured into a medical-only company and listed on the NYSE, keeping only a non-controlling interest in its former adult-use business. Our guide to how marijuana stocks work covers this in detail.
Legal reversal
The April order is being challenged in the D.C. Circuit. Nebraska, Indiana and Louisiana petitioned for review on May 22, 2026 and asked the court to vacate the order. Any company whose 2026 results depend on the order carries that risk.
How big is the hemp market?
USDA’s National Agricultural Statistics Service (NASS) runs the main federal survey of hemp production. Its National Hemp Report, released April 16, 2026, gives these figures for the 2025 crop:
| Segment (2025) | Area harvested | Value of production |
|---|---|---|
| All hemp, open field and under protection | n/a | $739 million (up 64% from 2024) |
| Floral hemp in the open | 16,880 acres | $574 million |
| Grain hemp in the open | 7,515 acres | $8.09 million |
| Fiber hemp in the open | 21,693 acres | $13.5 million |
| Seed hemp in the open | 3,537 acres | $49.7 million |
Two points matter for investors. First, these are farm-gate values of the crop, not retail sales of finished products, so they are not the same as “market size” figures in promotional material. Second, floral hemp, the segment most tied to CBD and cannabinoid products, accounts for most of the value. That is also the segment most exposed to the new per-container cap. Fiber and grain are far smaller in dollar terms but face much less regulatory risk.
Illustrative check: if a hemp fiber processor claims it will soon reach $50 million in annual revenue from U.S.-grown fiber, compare that with the $13.5 million NASS valued the entire 2025 U.S. open-field fiber crop at. Processing adds value, and imports or new acreage could change the picture, but a gap that size calls for a clear explanation in the company’s filings.
When the lines blur
Some companies operate in more than one category. A brand may sell hemp CBD nationally and marijuana products in licensed states. A Canadian producer may sell hemp-derived products in the U.S. while holding conditional rights to U.S. marijuana businesses. When that happens, the riskier activity usually sets the terms for the whole company’s banking, listing and tax position. Read the segment note and risk factors to see:
- what share of revenue comes from each category;
- whether hemp-derived products will still qualify once the new definition takes effect December 11, 2026;
- whether any marijuana activity is adult-use, which remains Schedule I and subject to 280E; and
- how the company describes its exposure to FDA policy.
Our framework for evaluating hemp and CBD companies shows how to apply these checks to a single company.
Frequently asked questions
Are hemp stocks safer than marijuana stocks?
They face different risks, not necessarily smaller ones. Compliant hemp avoids 280E and marijuana banking rules, but CBD and cannabinoid companies face FDA limits and the new per-container THC cap. Small hemp companies can also be thinly traded and poorly disclosed.
Did rescheduling affect hemp companies?
Not directly. The April 2026 order says it does not change hemp’s status. Hemp-derived products that fail the new hemp definition would be treated as marijuana, and would then follow whatever schedule applies to that marijuana.
When does the new hemp definition take effect?
As of November 19, 2026, the exclusion for cannabinoids the plant cannot naturally produce took effect November 12, 2026, and most other changes are scheduled for December 11, 2026. Bills to delay further are pending but not law.
Can CBD be sold as a dietary supplement?
FDA’s position is no. It considers CBD and THC products excluded from the dietary supplement definition, and treats adding them to food in interstate commerce as prohibited.
Do hemp businesses face Section 280E?
Not if their products meet the federal hemp definition, because 280E applies only to trafficking in Schedule I or II controlled substances.
Rules change; confirm with your state department of agriculture and USDA AMS before acting.
Sources
Credit: the facts, figures and rules in this article come from the organizations and authors listed below. All credit for their research and data belongs to them; follow the links to read the originals.
- Congressional Research Service, Delay in Changes to Hemp Definition: Cannabinoids Not Capable of Being Naturally Produced by the Cannabis Plant, LSB11496 (2026)
- U.S. Department of Justice / DEA, Final Rule: Rescheduling of FDA-Approved Products Containing Marijuana and State-Licensed Medical Marijuana to Schedule III, 91 FR 22714 (2026)
- The White House, Executive Order 14370: Increasing Medical Marijuana and Cannabidiol Research, 90 FR 60541 (2025)
- U.S. Food and Drug Administration, FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
- FinCEN, FIN-2020-G001: Due Diligence Requirements under the Bank Secrecy Act for Hemp-Related Business Customers (2020)
- FinCEN, FIN-2014-G001: BSA Expectations Regarding Marijuana-Related Businesses (2014)
- 26 U.S.C. § 280E, Expenditures in connection with the illegal sale of drugs (Legal Information Institute)
- U.S. Department of the Treasury, Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling (2026)
- Congress.gov, S. 4942, SAFE Banking Act of 2026, All Actions (2026)
- Congress.gov, H.R. 9471, SAFE Banking Act of 2026, All Actions (2026)
- State of Nebraska et al. v. U.S. Department of Justice et al., Petition for Review, D.C. Cir. No. 26-1130 (2026)
- USDA National Agricultural Statistics Service, National Hemp Report (April 16, 2026)
- SEC Office of Investor Education and Advocacy, Investor Alert: Marijuana Investments and Fraud (2018)
- Trulieve Cannabis Corp., Form 10-K for fiscal year 2025, SEC EDGAR (2026)
- Trulieve Cannabis Corp., Form 10-Q for the quarter ended September 30, 2026, SEC EDGAR (2026)
Figures last checked: November 19, 2026.
🌱 Finished reading? You earned 5 seeds.
Every article you read to the end earns seeds in Hemp Empire, our free hemp farming tycoon game. Play now →
Some links may be affiliate links. As an Amazon Associate, HempDollars earns from qualifying purchases.


Leave a Reply